EGFR and non-small cell lung carcinoma: In non-small cell lung cancer, IGF1R hyperactivity is related to acquired resistance to erlotinib, and simultaneous inhibition of EGFR and IGF1R is effective to prevent and also to overcome erlotinib resistance [64].